Multiple myeloma cells’ capacity to decompose H(2)O(2) determines lenalidomide sensitivity

Lenalidomide is an immunomodulatory drug (IMiDs) with clinical efficacy in multiple myeloma (MM) and other late B-cell neoplasms. Although cereblon (CRBN) is an essential requirement for IMiD action, the complete molecular and biochemical mechanisms responsible for lenalidomide-mediated sensitivity...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Sebastian, Sinto, Zhu, Yuan X., Braggio, Esteban, Shi, Chang-Xin, Panchabhai, Sonali C., Van Wier, Scott A., Ahmann, Greg J., Chesi, Marta, Bergsagel, P. Leif, Stewart, A. Keith, Fonseca, Rafael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2017
Aiheet:
Lymphoid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5324717/
https://ncbi.nlm.nih.gov/pubmed/28028022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-09-738872
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia